Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.82
−$0.12 · -1.51%
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Previous close
$7.82
−$0.12 · -1.51%
After-hours
$7.70
−$0.12 · -1.53%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Day range
Current $7.82
52-week range
Current $7.82
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
38
Expensive
Sentiment
60
Mixed
Risk
75
High Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Day range
Current $7.82
52-week range
Current $7.82
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 157.7M USD | 124.52M USD | 86.14M USD | 82.27M USD | 51.1M USD |
| Selling, general, and administrative | 21M USD | 17.74M USD | 18.82M USD | 24.71M USD | 20.39M USD |
| Operating expenses | 178.7M USD | 142.26M USD | 104.96M USD | 106.99M USD | 71.49M USD |
| Interest income | 16.22M USD | 12.68M USD | 8.32M USD | 2.23M USD | 442K USD |
| Depreciation and amortization | 490K USD | 393K USD | 377K USD | 357K USD | 163K USD |
| Operating income | −178.7M USD | −142.26M USD | −104.96M USD | −106.99M USD | −71.49M USD |
| Net income | −162.45M USD | −129.47M USD | −96.66M USD | −104.79M USD | −71.1M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$28.33
262.28% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI27.24M0.00%2.3T USD0.03%$379.56-0.39%
State Street SPDR S&P Biotech ETFXBI17.51M0.17%10.11B USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM16.35M0.02%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF6.88M0.01%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO4.7M0.03%18B USD0.06%$112.1-0.10%
Dimensional - US Small Cap ETFDFAS4.53M0.01%33.66B USD0.31%$78.10+0.23%
iShares Biotechnology ETFIBB4.22M0.04%10.41B USD0.44%$200.48-1.41%
Fidelity Enhanced Small Cap ETFFESM3.74M0.06%6.41B USD0.28%$45.25+0.07%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
